PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Antithrombotics - Market size and forecast 2018-2023 • Vasodilators - Market size and forecast 2018-2023 • Thrombolytics - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • MI type PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Stem cell therapies for MI • Advanced diagnostic modalities for MI • Rising number of patient-support initiatives PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Bayer AG • Bristol-Myers Squibb Company • Eli Lilly and Company • Pfizer Inc. PART 16: APPENDIX • Research methodology • List of abbreviations PART 17: EXPLORE TECHNAVIO   Exhibit 01: Global cardiovascular disorder treatment market Exhibit 02: Segments of global cardiovascular disorder treatment market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline molecules for MI Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Antithrombotics - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Antithrombotics - Year-over-year growth 2019-2023 (%) Exhibit 22: Vasodilators - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Vasodilators - Year-over-year growth 2019-2023 (%) Exhibit 24: Thrombolytics - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Activase sales in $ million Exhibit 26: Thrombolytics - Year-over-year growth 2019-2023 (%) Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Repatha sales $ million Exhibit 29: Others - Year-over-year growth 2019-2023 (%) Exhibit 30: Market opportunity by product Exhibit 31: Customer landscape Exhibit 32: Market share by geography 2018-2023 (%) Exhibit 33: Geographic comparison Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 35: North America - Year-over-year growth 2019-2023 (%) Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Sales of NOACs during 2015-2017 in $ million Exhibit 45: Patent expiration dates of approved branded drugs for MI Exhibit 46: Impact of drivers and challenges Exhibit 47: Stem cell therapies for MI Exhibit 48: Patient support programs Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: AstraZeneca - Vendor overview Exhibit 55: AstraZeneca - Business segments Exhibit 56: AstraZeneca - Organizational developments Exhibit 57: AstraZeneca - Geographic focus Exhibit 58: AstraZeneca - Key offerings Exhibit 59: Bayer AG - Vendor overview Exhibit 60: Bayer AG - Business segments Exhibit 61: Bayer AG - Organizational developments Exhibit 62: Bayer AG - Geographic focus Exhibit 63: Bayer AG - Segment focus Exhibit 64: Bayer AG - Key offerings Exhibit 65: Bristol-Myers Squibb Company - Vendor overview Exhibit 66: Bristol-Myers Squibb Company - Business segments Exhibit 67: Bristol-Myers Squibb Company - Organizational developments Exhibit 68: Bristol-Myers Squibb Company - Geographic focus Exhibit 69: Bristol-Myers Squibb Company - Key offerings Exhibit 70: Eli Lilly and Company - Vendor overview Exhibit 71: Eli Lilly and Company - Business segments Exhibit 72: Eli Lilly and Company - Organizational developments Exhibit 73: Eli Lilly and Company - Geographic focus Exhibit 74: Eli Lilly and Company - Segment focus Exhibit 75: Eli Lilly and Company - Key offerings Exhibit 76: Pfizer Inc. - Vendor overview Exhibit 77: Pfizer Inc. - Business segments Exhibit 78: Pfizer Inc. - Organizational developments Exhibit 79: Pfizer Inc. - Geographic focus Exhibit 80: Pfizer Inc. - Segment focus Exhibit 81: Pfizer Inc. - Key offerings Exhibit 82: Validation techniques employed for market sizing  

AstraZeneca Bayer AG Bristol-Myers Squibb Company Eli Lilly and Company Pfizer